- Home
- RLAY vs ARQT Comparison
RLAY vs ARQT Comparison
Compare RLAY & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | ARQT |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RLAY | ARQT |
|---|---|---|
| Price | $19.18 | $25.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $19.50 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.78 | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | $15,355,000.00 | ★ $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | $324.03 | $29.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 53.44 | ★ 91.34 |
| 52 Week Low | $3.03 | $13.70 |
| 52 Week High | $20.79 | $31.77 |
Technical Indicators
Market Signals| Indicator | RLAY | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.16 |
| Support Level | N/A | $24.96 |
| Resistance Level | N/A | $27.26 |
| Average True Range (ATR) | 0.00 | 1.01 |
| MACD | 0.00 | -0.34 |
| Stochastic Oscillator | 0.00 | 17.01 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.